Method for production of mutant-type human erythropoietin
US10604779B2 · kind B2 · utility
0Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 7, 2017 |
| Grant date | Mar 31, 2020 |
| Priority date | — |
| Expiry date | Mar 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/52
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.